Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)
Reference52 articles.
1. American Cancer Society. Key statistics for lung cancer; 2019. Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html. Accessed July 12,2019.
2. Cancer statistics, 2019
3. National Cancer Institut. Surveillance, epidemiology, and end results program; 2019. Available from: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed Jul 12,2019.
4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
5. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献